Selective PPARγ antagonist; antidiabetic and antiobesity agent. Attenuates troglitazone-induced PPARγ transcriptional activity (IC50 = 140 μM) without affecting ligand-stimulated PPARα, PPARβ or FXR transcriptional activity. Inhibits PPARγ-dependent adipocyte differentiation and growth in vitro and in vivo. Improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo.